Antioxidant properties of ursodeoxycholic acid

被引:85
作者
Lapenna, D [1 ]
Ciofani, G [1 ]
Festi, D [1 ]
Neri, M [1 ]
Pierdomenico, SD [1 ]
Giamberardino, MA [1 ]
Cuccurullo, F [1 ]
机构
[1] Univ G DAnnunzio, Fac Med & Chirurg, Dipartimento Med & Sci Invecchiamento, I-66100 Chieti, Italy
关键词
ursodeoxycholic acid; antioxidant; hydroxyl radical; iron; lipid peroxidation; oxidative stress;
D O I
10.1016/S0006-2952(02)01391-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We have investigated potential antioxidant properties of the clinically relevant bile acid UDCA, which reaches therapeutic concentrations up to 0.09 and 29 mM, respectively, in human plasma and bile. UDCA was an excellent scavenger of OH. generated by FeCl3-EDTA, H2O2 and ascorbate in the deoxyribose oxidation test, showing ICmin in and IC50 values of 0.02 and 0.2 mM, respectively, and a second-order rate constant for reaction with OH. of 2 0.1 x 10(10) M-1 s(-1). Notably, the drug could enhance at 1.5 mM concentration the antioxidant capacity of human bile against OH.-induced deoxyribose oxidation. UDCA also showed antioxidant effects in the deoxyribose test performed with nonchelated iron ions, such as Fe2+ plus H2O2 (ICmin: 7 MM, IC50: 20 mM) or Fe3+ plus H2O2 and ascorbate (ICmin: 0.3 mM, IC50: 5 mM), and inhibited ferrozine-Fe2+ and desferrioxamine-Fe3+ complexes formation with IC50 values of, respectively, 12 and 0.3 mM, indicating that the drug interacts more with iron(III) than with iron(II). Moreover, UDCA significantly inhibited phospholipid liposome peroxidation induced by the OH.-generating system FeC13-EDTA, H2O2 and ascorbate (ICmin: 0.75 mM, IC50: 3 mM), and by peroxyl radicals generated in the aqueous phase by AAPH (ICmin: 8 mM, IC50: 14 mM). UDCA, even at 25 MM concentration, was ineffective on the lipoperoxidation mediated by Fe2+ alone, but at the same concentration counteracted significantly that by Fe3+ plus ascorbate, further pointing to its preferential antioxidant interaction with iron(III). In conclusion, UDCA has direct antioxidant properties, which are especially relevant against Fe3+- and OH.-dependent biomolecular oxidative damage; such properties are evident at therapeutically relevant drug concentrations, suggesting that UDCA could act as an antioxidant in vivo. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:1661 / 1667
页数:7
相关论文
共 50 条
  • [31] Anticarcinogenic effects of ursodeoxycholic acid in pancreatic adenocarcinoma cell models
    Kovacs, Patrik
    Schwarcz, Szandra
    Nyerges, Petra
    Biro, Timea Ingrid
    Ujlaki, Gyula
    Bai, Peter
    Miko, Edit
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12
  • [32] Role of ursodeoxycholic acid in prevention of hepatotoxicity caused by amoxicillin-clavulanic acid in rats
    El-Sherbiny, Gamal A.
    Taye, Ashraf
    Abdel-Raheem, Ihab T.
    ANNALS OF HEPATOLOGY, 2009, 8 (02) : 134 - 140
  • [33] Drug reaction to ursodeoxycholic acid:: Lichenoid drug eruption in an infant using ursodeoxycholic acid for neonatal hepatitis
    Büyükgebiz, B
    Arslan, N
    Oztürk, Y
    Soyal, C
    Lebe, B
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2002, 35 (03) : 384 - 386
  • [34] Anticholestatic mechanisms of ursodeoxycholic acid in lipopolysaccharide-induced cholestasis
    Razori, Maria Valeria
    Maidagan, Paula M.
    Ciriaci, Nadia
    Andermatten, Romina B.
    Barosso, Ismael R.
    Martin, Pamela L.
    Basiglio, Cecilia L.
    Sanchez Pozzi, Enrique J.
    Laura Ruiz, Maria
    Roma, Marcelo G.
    BIOCHEMICAL PHARMACOLOGY, 2019, 168 : 48 - 56
  • [35] Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis
    Leuschner, M
    Guldutuna, S
    You, TG
    Hubner, K
    Bhatti, S
    Leuschner, U
    JOURNAL OF HEPATOLOGY, 1996, 25 (01) : 49 - 57
  • [36] In vitro and in vivo antioxidant properties of chlorogenic acid and caffeic acid
    Sato, Yuki
    Itagaki, Shirou
    Kurokawa, Toshimitsu
    Ogura, Jiro
    Kobayashi, Masaki
    Hirano, Takeshi
    Sugawara, Mitsuru
    Iseki, Ken
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2011, 403 (1-2) : 136 - 138
  • [37] Ursodeoxycholic acid in the treatment of liver diseases
    Saksena, S
    Tandon, RK
    POSTGRADUATE MEDICAL JOURNAL, 1997, 73 (856) : 75 - 80
  • [38] Increased prescribing of ursodeoxycholic acid in Norway
    Espen Skarstein Kolberg
    Morten Tranung
    Kristin Matre Aasarød
    International Journal of Clinical Pharmacy, 2018, 40 : 1454 - 1457
  • [39] Influence of Cholestasis on Absorption of Ursodeoxycholic Acid
    Peter Sauer
    Christine Benz
    Gerda Rudolph
    Petra Kloters-Plachky
    Wolfgang Stremmel
    Adolf Stiehl
    Digestive Diseases and Sciences, 1999, 44 : 817 - 822
  • [40] Statins and ursodeoxycholic acid: cooperation or neutrality?
    Grigorieva, I. N.
    Pozdnyakov, Y. M.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2009, 5 (06) : 51 - 54